Featured Press Releases

Signaling exciting growth, Modular Devices welcomes Jason Thompson and Stephanie Powers Kurtz to the Cleanrooms Sales Team

Signaling exciting growth, Modular Devices welcomes Jason Thompson and Stephanie Powers Kurtz to the Cleanrooms Sales Team

Fresenius-Kabi_17122024

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

  • 17 Dec 2024

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is...

Long Island University alumnus Dr. Howard Murad

Long Island University alumnus Dr. Howard Murad '62 launches the Inclusive Wellness Initiative with the Arnold & Marie Schwartz College of Pharmacy and Health Sciences

Mayo Clinic researchers have developed a first-in-kind, fully humanized 3D bioprinted human skin model using CollPlant

Mayo Clinic researchers have developed a first-in-kind, fully humanized 3D bioprinted human skin model using CollPlant's rhCollagen-based BioInk

To expand biopharma services with its liquid biopsy capabilities, Precision for Medicine partners with SOPHiA GENETICS on the SOPHiA DDM™ platform

To expand biopharma services with its liquid biopsy capabilities, Precision for Medicine partners with SOPHiA GENETICS on the SOPHiA DDM™ platform

Lansinoh® Launched NaturalWave® Double Electric Breast Pump Featuring Exclusive Flutter Technology for Increased Milk Output

Lansinoh® Launched NaturalWave® Double Electric Breast Pump Featuring Exclusive Flutter Technology for Increased Milk Output

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

Abbott receives FDA authorization for the world’s first dual glucose-ketone sensing technology for people with diabetes

  • Abbott
  • 26 Aug 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

  • Jazz Pharmaceuticals plc
  • 25 Aug 2026
European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

European Commission Approves DAYBU® (Trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms Associated with Rett Syndrome in the European Union

  • Acadia Pharmaceuticals Inc.
  • 24 Aug 2026
Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

Upsher-Smith Expands Neurology Portfolio with the Launch of Glatiramer Acetate Injection

  • Upsher-Smith Laboratories, LLC
  • 21 Aug 2026
Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

Dunbar Pharma Brings First Plant-Derived Dronabinol API to the UK Market Through IPS Pharma

  • Dunbar Pharmaceuticals
  • 18 Aug 2026
Former DePuy Synthes U.S. President Joins Peptilogics Board

Former DePuy Synthes U.S. President Joins Peptilogics Board

  • Peptilogics
  • 18 Aug 2026

Most Popular
August   2026
M T W T F S S
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.